The University Clinical Center Tuzla (UKC Tuzla) has introduced the Luminex 200, a state-of-the-art platform that marks a significant advancement in laboratory diagnostics and transplant immunology. To ensure the effective integration of this cutting-edge technology, a multi-day training session was conducted for healthcare professionals from the Polyclinic for Laboratory Diagnostics, the Department of Pathology, and the Department of Microbiology.
During the training, biologists and clinical immunologists gained hands-on experience and in-depth knowledge of the Luminex 200 system, equipping them with the expertise to optimize its application in clinical practice. This acquisition represents a crucial step in modernizing diagnostic procedures and enhancing the transplantation program at UKC Tuzla.
Prof. Dr. Nijaz Tihić, Head of the Polyclinic for Laboratory Diagnostics at the University Clinical Center Tuzla and a specialist in microbiology, highlighted the significance of the Luminex 200 platform in advancing transplant immunology and laboratory diagnostics:
“The Luminex 200 is a flow cytometry-based platform utilizing xMAP (Multi-Analyte Profiling) technology, where ‘x’ represents various biomarkers—including proteins, nucleic acids, and polysaccharides—that can be analyzed simultaneously. This system enables the testing of up to 100 different parameters in a single sample, using minimal sample volume. At UKC Tuzla, the Luminex 200 will be instrumental in HLA typing and the detection of HLA antibodies. It will facilitate HLA typing for A, B, C, DRB1, DQ, and DP loci, as well as KIR gene typing. Additionally, the platform will allow comprehensive screening for HLA class I and class II antibodies, as well as the detection of HLA antibodies against specific antigens.”
Prof. Dr. Tihić further emphasized the critical role of these analyses in transplantation, noting that they will enhance donor-recipient matching and improve post-transplant patient monitoring. In addition to HLA typing and antibody detection, the Luminex 200 platform will enable the assessment of various cytokines, providing valuable insights into immune responses and the risk of graft rejection.
Prof. Dr. Šekib Umihanić, Director of the University Clinical Center Tuzla, underscored the importance of modernizing laboratory diagnostics and advancing the transplantation program:”The acquisition of the Luminex 200 marks another step forward in enhancing our laboratory capabilities and improving the transplantation program at UKC Tuzla. This advanced technology will enable a more efficient, safer, and more successful transplantation process by providing our staff with precise and rapid diagnostic tools—essential for delivering high-quality medical care. With the continued support of the Government of Tuzla Canton, we remain committed to further investments that will position UKC Tuzla at the forefront of these critical medical fields.”
